Vycor Medical Inc. · OTC:VYCO

Vycor Medical — Investor Presentation (February 2023)

27 slides from Vycor Medical's investor presentation, February 2023

  1. Slide 1: Corporate Presentation 2023

    OTCQB:VYCO Corporate Presentation 2023

  2. Slide 2: Safe Harbor Statement

    OTCQB:VYCO Safe Harbor Statement Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimat

  3. Slide 3: Who We Are

    OTCQB:VYCO Who We Are  Vycor Medical is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions.  We have a portfolio of FDA cleared medical solutions that are changing and improving lives every day.  We operate two business units: Vycor Medica

  4. Slide 4: Our Two Product Lines

    OTCQB:VYCO Our Two Product Lines ViewSite™ NovaVision has the most comprehensive, commercially available Lead product ViewSite™ Brain Access System (VBAS) is a and clinically supported family of complementary therapies that revolutionary neurosurgical device used to retract and gain diagnose (VIDIT)

  5. Slide 5: ViewSite Brain Access System

    OTCQB:VYCO ViewSite Brain Access System “It is the ideal system for providing deep brain access through a smaller incision.” -Neurosurgeon Quote 5

  6. Slide 6: The Future Standard of Care

    OTCQB:VYCO The Future Standard of Care • Less brain tissue damage Old Blade/Ribbon Retractor Technology • Less invasive: requires smaller opening • Better access • Better visibility • Self-contained working channel • Reduced operating and recovery time VS. VBAS Next Generation Technology Allows for

  7. Slide 7: Market and Clinical Need for VBAS

    OTCQB:VYCO Market and Clinical Need for VBAS  Since the introduction of the first operative microscope 50+ years ago, microsurgery (and more recently endoscopic surgery) has become an indispensable technique in neurosurgery  In any surgical procedure adequate visualization of the operative field i

  8. Slide 8: How VBAS Addresses the Market's Clinical Needs

    OTCQB:VYCO How VBAS Addresses the Market’s Clinical Needs Superior Shape • The VBAS tubular shape disperses Discoloration of tissue retraction forces over a greater surface near the retractor tip area and has no edges where pressure build up is most common • Blunt tip allows for progressive dilation

  9. Slide 9: How VBAS Addresses the Market's Clinical Needs

    OTCQB:VYCO How VBAS Addresses the Market’s Clinical Needs Superior Field of View Surgical Field of View • Made of polished transparent polycarbonate Standard Retractor VBAS • Significantly increases the surgeons vision through clear walls • Allows for continual monitoring of surrounding tissue and s

  10. Slide 10: How VBAS Addresses the Market's Clinical Needs

    OTCQB:VYCO How VBAS Addresses the Market’s Clinical Needs Improved Working Channel • Elliptical shape provides a widened working channel in one access, gives the surgeon greater working room allowing for bimanual surgical maneuvering • The contained working channel provides protection of peripheral

  11. Slide 11: How VBAS Addresses the Market's Clinical Needs

    OTCQB:VYCO How VBAS Addresses the Market’s Clinical Needs Compatible with Neuronavigation • The tip of the VBAS introducer literally becomes the “pointer” on the neuro- navigation system, allowing for real time monitoring of its position • Clip of the recently launched VBAS AC locks in place the mos

  12. Slide 12: VBAS Saves Lives

    OTCQB:VYCO VBAS Saves Lives Previously Inoperable…Now Operable “Her case would have been inoperable via a traditional surgery, because she was taking Avastin®, which delays surgical wound healing. “The VBAS’ minimally invasive nature enabled the surgeon to gain access to the target through only a 3c

  13. Slide 13: Benefits Evidenced Through Extensive Clinical Data

    OTCQB:VYCO Benefits Evidenced Through Extensive Clinical Data  Build up of clinical evidence to support the VBAS advantages has been a key management objective  VBAS has now been the subject of 29 peer reviewed studies and 12 other clinical papers  Studies now conclusively point to reduced white

  14. Slide 14: ICH New Exciting Opportunity

    OTCQB:VYCO ICH New Exciting Opportunity 14

  15. Slide 15: Validated Technology

    OTCQB:VYCO Validated Technology Approved for Use in 200+ US Hospitals  Significant body of clinical papers and studies evidence VBAS’ clinical superiority and improved patient outcomes  International presence with regulatory approvals in key international markets  Technology protected by 31 grant

  16. Slide 16: Virtual Company: Reduces Cost

    OTCQB:VYCO Virtual Company: Reduces Cost  Vycor operates a “virtual outsourced” business model to focus its resources on product development and direct targeted marketing to physicians and hospitals  Manufacturing: outsourced to qualified sub-contract manufacturer  US sales: outsourced to 20 dist

  17. Slide 17: NovaVision

    OTCQB:VYCO NovaVision NovaVision’s Suite of Complementary Therapies Addresses Patients “We do not need a new brain, but with Vision Disorders Resulting from Stroke or Brain Injury innovative methods of treatment to overcome the functional consequences of brain injury” - Prof. Josef Zihl, Ph.D., Prof

  18. Slide 18: Multi-Billion Dollar Market Opportunity

    OTCQB:VYCO Multi-Billion Dollar Market Opportunity 8 Million Stroke Survivors in the U.S.1 US/Europe & Global Market Opportunity1 Vision loss from stroke and $13B traumatic brain injury (TBI) has been a big unaddressed issue, 30% each year, 600,000 new people Suffer from suffer from vision disorders

  19. Slide 19: An Important Therapy for Daily Life

    OTCQB:VYCO An Important Therapy for Daily Life “My vision began coming back after the first month of therapy…I passed my driving test, can read normally, and enjoy driving my boat on the lake…my life is back to normal.” – Stroke survivor and VRT patient Pre-VRT Post-VRT The Impact on Daily Lives Can

  20. Slide 20: ... And it Works

    OTCQB:VYCO … And it Works Clinically Demonstrated to Restore and Make the Most of Remaining Vision “I can't put a value on what I have • VRT: 15 years of research, 20 clinical studies including a 302 gained with NeuroEyeCoach, I can just say thank you with all that I am.” patient study in which nota

  21. Slide 21: NovaVision Therapies: From Clinic to Home

    OTCQB:VYCO NovaVision Therapies: From Clinic to Home Continual supervision and support from clinic to home for Rehab Clinics/Centers for Patients testing and treatment in their home Visual Diagnostics (VIDIT) NeuroEyeCoach Testing of the central Training can be started in visual field to identify cl

  22. Slide 22: NovaVision Today

    OTCQB:VYCO NovaVision Today For patients: Most comprehensive, commercially available and clinically- supported line of complementary therapies: Visual Restoration Therapy® (VRT): the only FDA-cleared therapy for the restoration of vision loss as the result of stroke or brain damage NeuroEyeCoach®: h

  23. Slide 23: NeuroEyeCoach Highly Effective

    OTCQB:VYCO NeuroEyeCoach Highly Effective • The only dedicated visual training program specifically designed to improve scanning and eye movement: ➢ Other scanning programs in use at clinics are part of aggregated modular systems ➢ Can be completed during patient’s stay in clinic or be completed at

  24. Slide 24: NeuroEyeCoach Study – A Game Changer

    OTCQB:VYCO NeuroEyeCoach Study – A Game Changer Published in Cortex, this is the largest study completed to date in the neuro visual space • Analysed results of 296 patients who performed NeuroEyeCoach • Demonstrated dramatic improvement in patients’ ability to detect objects in the visual field by

  25. Slide 25: NEC Potential in Non-HealthCare Markets

    OTCQB:VYCO NEC Potential in Non-HealthCare Markets NovaVision believes there is potential to move into non-healthcare markets possibly even through a JV: • Strong potential for NeuroEyeCoach technology given its strong clinical data • Potential variants for non-medical use in sports, aviation, gamin

  26. Slide 26: Key Takeaways

    OTCQB:VYCO Key Takeaways  Significant barriers to entry:  Two “game changing” product lines  Robust patent portfolio; 61 granted and 11  Devices are FDA-cleared, development risk now off pending patents the table  Significant published clinical data supporting  Address significant markets – No

  27. Slide 27: Contact Us

    OTCQB:VYCO Contact Us Company Contacts Corporate Headquarters Our Websites 951 Broken Sound Parkway, www.vycormedical.com Peter Zachariou, CEO Suite 320, Boca Raton, FL 33487 www.vycorvbas.com David Cantor, President 561-558-2020 www.novavision.com [email protected] Adrian Liddell, CFO 27

Vycor Medical — Investor Presentation (February 2023) on 6ix